Chapter 75
Irritable Bowel Syndrome
Elizabeth J. Videlock,
Lin Chang,
Elizabeth J. Videlock
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Search for more papers by this authorLin Chang
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Search for more papers by this authorElizabeth J. Videlock,
Lin Chang,
Elizabeth J. Videlock
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Search for more papers by this authorLin Chang
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Search for more papers by this authorBook Editor(s):Daniel K. Podolsky MD,
Michael Camilleri MD,
J. Gregory Fitz MD FAASLD,
Anthony N. Kalloo MD,
Fergus Shanahan MD,
Timothy C. Wang MD,
Daniel K. Podolsky MD
President, University of Texas Southwestern Medical Center, Professor of Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA
Search for more papers by this authorMichael Camilleri MD
Executive Dean for Development, Atherton and Winifred W. Bean Professor, Professor of Medicine, Physiology and Pharmacology, Distinguished Investigator, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorJ. Gregory Fitz MD FAASLD
Executive Vice President for Academic Aff airs and Provost, University of Texas Southwestern Medical Center, Dean, Professor of Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX, USA
Search for more papers by this authorAnthony N. Kalloo MD
Professor of Medicine, Johns Hopkins University School of Medicine, Director, Division of Gastroenterology & Hepatology, Johns Hopkins Hospital, Baltimore, MD, USA
Search for more papers by this authorFergus Shanahan MD
Professor and Chair, Department of Medicine, Director, Alimentary Pharmabiotic Centre, University College Cork, National University of Ireland, Cork, Ireland
Search for more papers by this authorTimothy C. Wang MD
Chief, Division of Digestive and Liver Diseases, Silberberg Professor of Medicine, Department of Medicine and Irving Cancer Research Center, Columbia University Medical Center, New York, NY, USA
Search for more papers by this authorSummary
Irritable Bowel Syndrome (IBS) can be grouped into the functional somatic syndromes. The diagnostic criteria are focused on gastrointestinal (GI) symptoms, but it should be noted that extraintestinal symptoms are common in IBS and cluster analysis suggests that disorders such as IBS, temporomandibular joint disorder, (TMD), chronic pelvic pain, and chronic fatigue syndrome (CFS) among others coexist more frequently than would occur by chance. IBS has a very high prevalence, though it varies based on geographical region, diagnostic criteria and population studied. This chapter discusses the concepts of visceral sensitivity, peripheral/central sensitization and endogenous pain modulation of IBS. It describes the stress response system including the hypothalamic- pituitary-adrenal (HPA) axis, corticotropin-releasing factor (CRF), and the autonomic nervous system (ANS). The chapter discusses early adverse life events (EALs), immune activation, GI transit, motility, and secretion, serotonin, microbiota, postinfectious IBS, genetics and bile acid processing of the pathogenesis of IBS.
References
- Brandt L.J., Chey W.D., Foxx-Orenstein A.E., et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104: S1.
- Ford A.C., Talley N.J., Veldhuyzen van Zanten S.J., et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300: 1793.
- Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480.
- Mayer E.A., Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381.
- Palsson O.S., Whitehead W.E. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2013; 11: 208.
- Simren M., Barbara G., Flint H.J., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159.
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480.
- Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626.
- Whitehead WE, Palsson OS, Levy RR, et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102: 2767.
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712.
- Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653.
- Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45: II43.
- Drossman DA, Sandler RS, Mckee DC, et al. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982; 83: 529.
- Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283.
- Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005; 22: 935.
- Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365.
- Minocha A, Johnson WD, Abell TL, et al. Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study. Dig Dis Sci 2006; 51: 446.
- Saito YA, Talley NJ, Melton JL, et al. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003; 15: 687.
- Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104: S1.
- Drossman DA, Mckee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95: 701.
- Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927.
- Sandler RS, Drossman DA, Nathan HP, et al. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology 1984; 87: 314.
- Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96: 3122.
- Drossman DA, Li Z, Andruzzi E, et al. U.S. Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569.
- Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005; 100: 1174.
- Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 991.
- Sperber AD, Drossman DA, Quigley EM. The global perspective on irritable bowel syndrome: a Rome foundation-world gastroenterology organisation symposium. Am J Gastroenterol 2012; 107: 1602.
- Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the world gastroenterology organisation summit task force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356.
- Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009; 24: 1601.
- Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in india: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2008; 27: 22.
- El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171.
- Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654.
- Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910.
- Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 1064.
- Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 183.
- Koloski NA, Boyce PM, Jones MP, et al. What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? Are current IBS symptom thresholds clinically meaningful? Qual Life Res 2012; 21: 829.
- Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 124.
- Naliboff BD, Kim SE, Bolus R, et al. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol 2012; 107: 451.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473.
- Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004; 164: 1773.
- Pare P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in canada), a naturalistic study. Clin Ther 2006; 28: 1726.
- Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005; 11: S17.
- Dibonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011; 27: 2213.
- Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671.
- Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929.
-
Spiegel BM,
Harris LA,
Lucak SL, et al.
Predictors of work productivity in irritable bowel syndrome (IBS): results from the proof cohort.
Gastroenterology
2008;
134:
A.
10.1016/S0016-5085(08)60137-7 Google Scholar
- Everhart JE, Ruhl CE. Burden of digestive diseases in the united states part ii: lower gastrointestinal diseases. Gastroenterology 2009; 136: 741.
- Everhart JE. Functional intestinal disorders. Washington, DC: US Government Printing Office: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008 Contract No.: NIH Publication No. 09-6443.
- Ladabaum U, Boyd E, Zhao WK, et al. Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 2012; 10: 37.
- Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled us trial. Am J Gastroenterol 2010; 105: 859.
- Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770.
- Spiegel BM, Gralnek IM, Bolus R, et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62: 892.
- Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665.
- Lu CL, Liu CC, Fuh JL, et al. Irritable bowel syndrome and negative appendectomy: a prospective multivariable investigation. Gut 2007; 56: 655.
- Lieberman DA, Holub J, Eisen G, et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005; 62: 875.
- Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. Managed care perspective. Am J Gastroenterol 2003; 98: 600.
- Riedl A, Schmidtmann M, Stengel A, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res 2008; 64: 573.
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140.
- Walker EA, Katon WJ, Jemelka RP, et al. Comorbidity of gastrointestinal complaints, depression, and anxiety in the epidemiologic catchment area (ECA) study. Am J Med 1992; 92: 26S.
- Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108.
- North CS, Downs D, Clouse RE, et al. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004; 2: 787.
- Spiegel BM, Kanwal F, Naliboff B, et al. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2262.
- Saito YA, Petersen GM, Larson JJ, et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol 2010; 105: 833.
- Saito YA, Zimmerman JM, Harmsen WS, et al. Irritable bowel syndrome aggregates strongly in families: a family-based case-control study. Neurogastroenterol Motil 2008; 20: 790.
- Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75: 907.
- Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998; 93: 1311.
- Bengtson MB, Ronning T, Vatn MH, et al. Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754.
- Mohammed I, Cherkas LF, Riley SA, et al. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005; 100: 1340.
- Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001; 121: 799.
- Levy RL. Exploring the intergenerational transmission of illness behavior: from observations to experimental intervention. Ann Behav Med 2011; 41: 174.
- Levy RL, Whitehead WE, Von Korff MR, et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95: 451.
- Levy RL, Whitehead WE, Walker LS, et al. Increased somatic complaints and health-care utilization in children: effects of parent IBS status and parent response to gastrointestinal symptoms. Am J Gastroenterol 2004; 99: 2442.
- Whitehead WE, Winget C, Fedoravicius AS, et al. Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982; 27: 202.
- Kalantar JS, Locke GR, Zinsmeister AR, et al. Familial aggregation of irritable bowel syndrome: a prospective study. Gut 2003; 52: 1703.
- Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psychiatry 1988; 145: 1358.
- Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007; 5: 465.
- Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779.
- Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096.
- Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979.
- Marshall JK, Thabane M, Borgaonkar MR, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5: 457.
- Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107: 891.
- Dizdar V, Gilja OH, Hausken T. Increased visceral sensitivity in giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil 2007; 19: 977.
- Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007; 102: 1064.
- Marshall JK, Thabane M, Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445.
- Cohen E, Fuller G, Bolus R, et al. Increased risk for irritable bowel syndrome following acute diverticulitis. Clin Gastroenterol Hepatol 2013; 11: 1614.
- Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825.
- Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651.
- Chitkara DK, Van Tilburg M, Blois-Martin N, et al. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 2008; 103: 765.
- Bradford K, Shih W, Videlock EJ, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012; 10: 385.
- Anand KJ, Runeson B, Jacobson B. Gastric suction at birth associated with long-term risk for functional intestinal disorders in later life. J Pediatr 2004; 144: 449.
- Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990; 113: 828.
- Klooker TK, Braak B, Painter RC, et al. Exposure to severe wartime conditions in early life is associated with an increased risk of irritable bowel syndrome: a population-based cohort study. Am J Gastroenterol 2009; 104: 2250.
- Gray GC, Reed RJ, Kaiser KS, et al. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee health study. Am J Epidemiol 2002; 155: 1033.
- Dunphy RC, Bridgewater L, Price DD, et al. Visceral and cutaneous hypersensitivity in Persian Gulf War veterans with chronic gastrointestinal symptoms. Pain 2003; 102: 79.
- Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748.
- Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381.
- Blackshaw LA, Brookes SJ, Grundy D, et al. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007; 19: 1.
- Kyloh M, Nicholas S, Zagorodnyuk VP, et al. Identification of the visceral pain pathway activated by noxious colorectal distension in mice. Front Neurosci 2011; 5: 16.
- Liu CN, Devor M, Waxman SG, et al. Subthreshold oscillations induced by spinal nerve injury in dissociated muscle and cutaneous afferents of mouse DRG. J Neurophysiol 2002; 87: 2009.
- Grundy D, Al-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130: 1391.
- Feng B, La JH, Schwartz ES, et al. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1085.
- Berthoud HR, Blackshaw LA, Brookes SJ, et al. Neuroanatomy of extrinsic afferents supplying the gastrointestinal tract. Neurogastroenterol Motil 2004; 16: 28.
- Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005; 257: 139.
- Al-Chaer E, Westlund K, Willis W. Sensitization of postsynaptic dorsal column neuronal responses by colon inflammation. Neuroreport 1997; 8: 3267.
- Mayer EA. Spinal and supraspinal modulation of visceral sensation. Gut 2000; 47: 69.
- Ludidi S, Conchillo JM, Keszthelyi D, et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012; 24: 729.
- Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125.
- Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187.
- Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40.
- Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771.
- Chang L, Mayer EA, Johnson T, et al. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000; 84: 297.
- Price DD, Craggs JG, Zhou Q, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. Neuroimage 2009; 47: 995.
- Wilder-Smith CH, Robert-Yap J. Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome. World J Gastroenterol 2007; 13: 3699.
- Posserud I, Syrous A, Lindstrom L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113.
- Cremonini F, Houghton LA, Camilleri M, et al. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 2005; 17: 810.
- Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil 2009; 21: 23.
- Camilleri M, Mckinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772.
- Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 458.
- Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 55.
- Poitras P, Riberdy Poitras M, Plourde V, et al. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002; 47: 914.
- Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219.
- Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303.
- Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095.
- Wiech K, Ploner M, Tracey I. Neurocognitive aspects of pain perception. Trends Cogn Sci 2008; 12: 306.
- Wiech K, Tracey I. The influence of negative emotions on pain: behavioral effects and neural mechanisms. Neuroimage 2009; 47: 987.
- Elsenbruch S, Rosenberger C, Enck P, et al. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010; 59: 489.
- Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115: 1263.
- Dorn SD, Palsson OS, Thiwan SIM, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202.
- Lackner JM, Coad ML, Mertz HR, et al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav Res Ther 2006; 44: 621.
- Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011; 140: 91.
- Larsson MB, Tillisch K, Craig AD, et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 2012; 142: 463.
- Davis KD, Pope G, Chen J, et al. Cortical thinning in IBS: implications for homeostatic, attention, and pain processing. Neurology 2008; 70: 153.
- Seminowicz DA, Labus JS, Bueller JA, et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 2010; 139: 48.
- Gibney SM, Gosselin RD, Dinan TG, et al. Colorectal distension-induced prefrontal cortex activation in the Wistar-Kyoto rat: implications for irritable bowel syndrome. Neuroscience 2010; 165: 675.
- Mayer EA, Berman S, Suyenobu B, et al. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398.
- Wilder-Smith CH, Schindler D, Lovblad K, et al. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595.
- King CD, Wong F, Currie T, et al. Deficiency in endogenous modulation of prolonged heat pain in patients with irritable bowel syndrome and temporomandibular disorder. Pain 2009; 143: 172.
- Piche M, Arsenault M, Poitras P, et al. Widespread hypersensitivity is related to altered pain inhibition processes in irritable bowel syndrome. Pain 2010; 148: 49.
- Piche M, Bouin M, Arsenault M, et al. Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes. Neuroscience 2011; 195: 166.
- Berman SM, Naliboff BD, Suyenobu B, et al. Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci 2008; 28: 349.
- Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765.
- Verne GN, Robinson ME, Vase L, et al. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105: 223.
- Bouin M, Delvaux M, Blanc C, et al. Intrarectal injection of glycerol induces hypersensitivity to rectal distension in healthy subjects without modifying rectal compliance. Eur J Gastroenterol Hepatol 2001; 13: 573.
- Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor trpv1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008; 57: 923.
- Cenac N, Altier C, Motta JP, et al. Potentiation of trpv4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity. Gut 2010; 59: 481.
- Zhao JH, Dong L, Shi HT, et al. The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients. Dig Dis Sci 2012; 57: 58.
- Verne GN, Himes NC, Robinson ME, et al. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003; 103: 99.
- Verne GN, Price DD, Callam CS, et al. Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors. J Pain 2012; 13: 901.
- Zhou QQ, Fillingim RB, Riley JL, et al. Central and peripheral hypersensitivity in the irritable bowel syndrome. Pain 2010; 148: 454.
- Rodrigues AC, Verne GN, Schmidt S, et al. Hypersensitivity to cutaneous thermal nociceptive stimuli in irritable bowel syndrome. Pain 2005; 115: 5.
- Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 7.
- Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995; 108: 636.
- Cook IJ, Van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727.
- Stabell N, Stubhaug A, Flaegstad T, et al. Increased pain sensitivity among adults reporting irritable bowel syndrome symptoms in a large population-based study. Pain 2013; 154: 385.
- Chang L, Berman S, Mayer EA, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003; 98: 1354.
- Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: S Fisher, J Reason (eds). Handbook of Life Stress, Cognition and Health. New York: John Wiley & Sons, 1988: 629.
- Mcewen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171.
- Bennett EJ, Tennant CC, Piesse C, et al. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256.
- Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400.
- Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102.
- Dickhaus B, Mayer EA, Firooz N, et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 135.
- Welgan P, Meshkinpour H, Hoehler F. The effect of stress on colon motor and electrical activity in irritable bowel syndrome. Psychosom Med 1985; 47: 139.
- Anda RF, Felitti VJ, Bremner JD, et al. The enduring effects of abuse and related adverse experiences in childhood. A convergence of evidence from neurobiology and epidemiology. Eur Arch Psychiatry Clin Neurosci 2006; 256: 174.
- Anda RF, Brown DW, Dube SR, et al. Adverse childhood experiences and chronic obstructive pulmonary disease in adults. Am J Prev Med 2008; 34: 396.
- Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001; 49: 1023.
- Coutinho SV, Plotsky PM, Sablad M, et al. Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 2002; 282: G307.
- Chung EKY, Zhang XJ, Li Z, et al. Neonatal maternal separation enhances central sensitivity to noxious colorectal distention in rat. Brain Res 2007; 1153: 68.
- O'mahony SM, Marchesi JR, Scully P, et al. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 2009; 65: 263.
- Soderholm JD, Yates DA, Gareau MG, et al. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1257.
- O'Mahony S, Chua AS, Quigley EM, et al. Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. Neurogastroenterol Motil 2008; 20: 680.
- Ren TH, Wu J, Yew D, et al. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2007; 292: G849.
- Tyler K, Moriceau S, Sullivan RM, et al. Long-term colonic hypersensitivity in adult rats induced by neonatal unpredictable vs predictable shock. Neurogastroenterol Motil 2007; 19: 761.
- Elzinga BM, Roelofs K, Tollenaar MS, et al. Diminished cortisol responses to psychosocial stress associated with lifetime adverse events a study among healthy young subjects. Psychoneuroendocrinology 2008; 33: 227.
- Rinne T, De Kloet ER, Wouters L, et al. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/ corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002; 52: 1102.
- Carpenter LL, Carvalho JP, Tyrka AR, et al. Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. Biol Psychiatry 2007; 62: 1080.
- Mcgowan PO, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12: 342.
- Labonte B, Yerko V, Gross J, et al. Differential glucocorticoid receptor exon 1(b), 1(c), and 1(h) expression and methylation in suicide completers with a history of childhood abuse. Biol Psychiatry 2012; 72: 41.
- Chang L, Iliopoulos D, Polytarchou C, et al. Glucocorticoid receptor gene methylation is a potential biomarker of irritable bowel syndrome. Gastroenterology 2012; 142: S176.
- Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42: 845.
- Myers B, Greenwood-Van Meerveld B. Elevated corticosterone in the amygdala leads to persistent increases in anxiety-like behavior and pain sensitivity. Behav Brain Res 2010; 214: 465.
- Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 2011; 141: 2098.
- Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011; 140: 761.
- Videlock EJ, Adeyemo M, Licudine A, et al. Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology 2009; 137: 1954.
- Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994; 106: 945.
- Jarrett ME, Burr RL, Cain KC, et al. Autonomic nervous system function during sleep among women with irritable bowel syndrome. Dig Dis Sci 2008; 53: 694.
- Heitkemper M, Jarrett M, Cain KC, et al. Autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci 2001; 46: 1276.
- Heitkemper M, Burr RL, Jarrett M, et al. Evidence for autonomic nervous system imbalance in women with irritable bowel syndrome. Dig Dis Sci 1998; 43: 2093.
- Alba-Delgado C, Llorca-Torralba M, Horrillo I, et al. Chronic pain leads to concomitant noradrenergic impairment and mood disorders. Biol Psychiatry 2013; 73: 54.
- Almy TP. Experimental studies on the irritable bowel syndrome. Am J Med 1951; 10: 60.
- Vassallo M, Camilleri M, Phillips SF, et al. Transit through the proximal colon influences stool weight in the irritable-bowel-syndrome. Gastroenterology 1992; 102: 102.
- Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499.
- Clemens CHM, Samsom M, Van Berge Henegouwen GP, et al. Abnormalities of left colonic motility in ambulant nonconstipated patients with irritable bowel syndrome. Dig Dis Sci 2003; 48: 74.
- Agrawal A, Houghton LA, Reilly B, et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009; 104: 1998.
- Kanazawa M, Palsson OS, Thiwan SI, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550.
- Suttor VP, Prott GM, Hansen RD, et al. Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome. Dis Colon Rectum 2010; 53: 156.
- Prott G, Shim L, Hansen R, et al. Relationships between pelvic floor symptoms and function in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 764.
- Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397.
- Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34.
- Houghton LA, Atkinson W, Lockhart C, et al. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 2007; 19: 724.
- Kilkens TO, Honig A, Van Nieuwenhoven MA, et al. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004; 53: 1794.
- Labus JS, Mayer EA, Jarcho J, et al. Acute tryptophan depletion alters the effective connectivity of emotional arousal circuitry during visceral stimuli in healthy women. Gut 2011; 60: 1196.
- Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523.
- Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205.
- Ohman L, Isaksson S, Lundgren A, et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980.
- Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392.
- Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778.
- Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693.
- Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689.
- Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012; 107: 75.
- Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213.
- Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636.
- Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262.
- Holmen N, Isaksson S, Simren M, et al. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 2007; 19: 119.
- Braak B, Klooker TK, Wouters MM, et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012; 107: 715.
- Schmulson M, Pulido-London D, Rodriguez O, et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747.
- Scully P, Mckernan DP, Keohane J, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235.
- Hod K, Dickman R, Sperber A, et al. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 1105.
- Mckernan DP, Gaszner G, Quigley EM, et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045.
- Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS ONE 2012; 7: e42777.
- Brint EK, Macsharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329.
- Barkhordari E, Rezaei N, Ansaripour B, et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010; 30: 74.
- Barkhordari E, Rezaei N, Mahmoudi M, et al. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation 2010; 33: 281.
- O'malley D, Liston M, Hyland NP, et al. Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2011; 300: G241.
- Dinan TG, Clarke G, Quigley EM, et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570.
- Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304.
- Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012; 24: 503.
- Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288.
- Zhou QQ, Zhang BY, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41.
- Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317.
- Gecse K, Roka R, Sera T, et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012; 85: 40.
- Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196.
- Bertiaux-Vandaele N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011; 106: 2165.
- Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804.
- Zhou QQ, Souba WW, Croce CM, et al. Microrna-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59: 775.
- Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903.
- Saunders PR, Kosecka U, Mckay DM, et al. Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine. Am J Physiol 1994; 267: G794.
- Santos J, Yang PC, Soderholm JD, et al. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001; 48: 630.
- Saunders PR, Santos J, Hanssen NP, et al. Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. Dig Dis Sci 2002; 47: 208.
- Gareau MG, Jury J, Yang PC, et al. Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance. Pediatr Res 2006; 59: 83.
- Bueno L, Fioramonti J. Protease-activated receptor 2 and gut permeability: a review. Neurogastroenterol Motil 2008; 20: 580.
- Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859.
- Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome Foundation Report. Gut 2013; 62: 159.
- Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373.
- Kerckhoffs AP, Samsom M, Van Der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887.
- Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35.
- Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557.
- Villarreal AA, Aberger FJ, Benrud R, et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17.
- Verdu EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182.
- Kim HJ, Camilleri M, Mckinzie S, et al. A randomized controlled trial of a probiotic, vsl#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895.
- Zareie M, Johnson-Henry K, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55: 1553.
- Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313.
- O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541.
- Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989; 30: 1099.
- Shepherd SJ, Parker FC, Muir JG, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6: 765.
- Husebye E, Hellstrom PM, Sundler F, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G368.
- Kashyap PC, Marcobal A, Ursell LK, et al. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 2013; 144: 967.
- Bailey MT, Lubach GR, Coe CL. Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr 2004; 38: 414.
-
Bailey MT,
Coe CL.
Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys.
Dev Psychobiol
1999;
35:
146.
10.1002/(SICI)1098-2302(199909)35:2<146::AID-DEV7>3.0.CO;2-G CAS PubMed Web of Science® Google Scholar
- Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306.
- Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599.
- Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009; 136: 2003.
- Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 48.
- Kiank C, Tache Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 2010; 24: 41.
- Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am 2011; 40: 45.
- Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNbeta3 825C>T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci 2012; 57: 2650.
- Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 979.
- Wang YM, Chang Y, Chang YY, et al. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil 2012; 24: 560.
- Kohen R, Jarrett ME, Cain KC, et al. The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome. Dig Dis Sci 2009; 54: 2663.
- Kapeller J, Houghton LA, Monnikes H, et al. First evidence for an association of a functional variant in the microrna-510 target site of the serotonin receptor-type 3e gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008; 17: 2967.
- Fukudo S, Kanazawa M, Mizuno T, et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage 2009; 47: 946.
- Kilpatrick LA, Labus JS, Coveleskie K, et al. The HTR3a polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 2011; 140: 1943.
- Sato N, Suzuki N, Sasaki A, et al. Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. PLoS ONE 2012; 7: e42450.
- Park JM, Choi MG, Cho YK, et al. Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. J Clin Gastroenterol 2011; 45: 45.
- Karling P, Danielsson A, Wikgren M, et al. The relationship between the val158met catechol-o-methyltransferase (COMT) polymorphism and irritable bowel syndrome. PLoS ONE 2011; 6: e18035.
- Romero-Valdovinos M, Gudino-Ramirez A, Reyes-Gordillo J, et al. Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep 2012; 39: 8837.
- Van Der Veek PP, Van Den Berg M, De Kroon YE, et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510.
- Spiller R, Swan C, Campbell E. Identifying and testing candidate genes underlying the inflammatory basis of irritable bowel syndrome. Gut 2011; 60: A164.
- Saito YA, Strege PR, Tester DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol 2009; 296: G211.
- Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425.
- Wong BS, Camilleri M, Carlson PJ, et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222.
- Camilleri M. Genetics of human gastrointestinal sensation. Neurogastroenterol Motil 2013; 25: 458.
- Kirwan WO, Smith AN, Mitchell WD, et al. Bile acids and colonic motility in the rabbit and the human. Gut 1975; 16: 894.
- Edwards CA, Brown S, Baxter AJ, et al. Effect of bile acid on anorectal function in man. Gut 1989; 30: 383.
- Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SEHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707.
- Ford AC. Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. Aliment Pharmacol Ther 2010; 31: 161.
- Gracie DJ, Kane JS, Mumtaz S, et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983.
- Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphac4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009; 21: 734.
- Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009.
- Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262.
- Palsson OS, Baggish JS, Turner MJ, et al. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012; 107: 286.
- Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther 2007; 25: 323.
- Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94: 1320.
- Chaudhary NA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31: 307.
- Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 108.
- Hellstrom PM, Saito YA, Bytzer P, et al. Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol 2011; 106: 1299.
- Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454.
- Tang YR, Yang WW, Wang YL, et al. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2012; 24: 702.
- Schmulson M, Lee OY, Chang L, et al. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94: 2929.
- Coffin B, Dapoigny M, Cloarec D, et al. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2004; 28: 11.
- Van Der Horst HE, Van Dulmen AM, Schellevis FG, et al. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel syndrome? Gut 1997; 41: 669.
- Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002; 123: 1686.
- Lee OY, Mayer EA, Schmulson M, et al. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001; 96: 2184.
- Simren M, Abrahamsson H, Svedlund J, et al. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol 2001; 36: 545.
- Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990; 34: 483.
- Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76.
- Heitkemper M, Jarrett M, Bond EF, et al. Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 2003; 5: 56.
- Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 2010; 32: 738.
- Houghton LA, Lea R, Jackson N, et al. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 471.
- Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team Report. Am J Gastroenterol 2011; 106: 1749.
- Drossman D. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000; 95: 974.
- Spiegel B, Strickland A, Naliboff BD, et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2536.
- Spiegel BM, Bolus R, Harris LA, et al. Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment Pharmacol Ther 2010; 32: 1192.
- Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006; 129: 174.
- Thompson W, Creed F, Drossman D. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5: 75.
- Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42: 690.
- Kellow JE. The “pro” case. The Rome III criteria. Neurogastroenterol Motil 2007; 19: 787.
- Tytgat GN. Foreword ii. In: D Drossman, E Corazziari, M Delvaux, et al. (eds). Rome III the Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates, Inc; 2006: 639.
- Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 2010; 105: 814.
- Ford AC, Talley NJ, Veldhuyzen Van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300: 1793.
- Engsbro AL, Begtrup LM, Kjeldsen J, et al. Patients suspected of irritable bowel syndrome–cross-sectional study exploring the sensitivity of Rome III criteria in primary care. Am J Gastroenterol 2013; 108: 972.
- Bellentani S, Baldoni P, Petrella S, et al. A simple score for the identification of patients at high risk of organic diseases of the colon in the family doctor consulting room. The local IBS study group. Fam Pract 1990; 7: 307.
- Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1.
- Whitehead WE, Palsson OS, Feld AD, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24: 137.
- Hammer J, Eslick GD, Howell SC, et al. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004; 53: 666.
- Lacy BE, Rosemore J, Robertson D, et al. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 2006; 41: 892.
- Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105: 848.
- Porter CK, Cash BD, Pimentel M, et al. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol 2012; 12: 55.
- Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002; 97: 2812.
- Tolliver BA, Herrera JL, Dipalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994; 89: 176.
- Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309.
- Jonefjall B, Strid H, Ohman L, et al. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil 2013; 25: 756.
- Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013; 17: 1.
- Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the united states: a large multicenter study. Arch Intern Med 2003; 163: 286.
- Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141: 1187.
- Mein SM, Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004; 19: 1199.
- Spiegel BMR, Derosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126: 1721.
- Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412.
- Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566.
- Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103: 958.
- Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334.
- Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802.
- Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci 2012; 57: 1321.
- Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 2013; 37: 1103.
- Williams C, Mccoll KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23: 3.
- Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol 2012; 107: 1793.
- Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008; 103: 2972.
- Vesa TH, Marteau P, Korpela R. Lactose intolerance. J Am Coll Nutr 2000; 19: 165S.
- Casellas F, Aparici A, Casaus M, et al. Subjective perception of lactose intolerance does not always indicate lactose malabsorption. Clin Gastroenterol Hepatol 2010; 8: 581.
- Lomer MCE, Parkes GC, Sanderson JD. Review article: lactose intolerance in clinical practice – myths and realities. Aliment Pharmacol Ther 2008; 27: 93.
- Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome–etiology, prevalence and consequences. Eur J Clin Nutr 2006; 60: 667.
- Kuiken SD, Lindeboom R, Tytgat GN, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 157.
- Schmulson M, Chang L, Naliboff B, et al. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol 2000; 95: 152.
- Sabate JM, Veyrac M, Mion F, et al. Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 484.
- Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: from animal models to drug development. Gut 2008; 57.
- Tornblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 2012; 107: 754.
- Bharucha AE, Dorn SD, Lembo A, et al. American gastroenterological association medical position statement on constipation. Gastroenterology 2013; 144: 211.
- Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008; 135: 1877.
- Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000; 49: 796.
- Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999.
- Chang L, Drossman D. Optimizing patient care: the psychological interview in irritable bowel syndrome. Clin Perspect 2002; 5: 336.
- Ringstrom G, Storsrud S, Posserud I, et al. Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. Eur J Gastroenterol Hepatol 2010; 22: 420.
- Ringstrom G, Storsrud S, Simren M. A comparison of a short nurse-based and a long multidisciplinary version of structured patient education in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2012; 24: 950.
- Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106: 508.
- Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459.
- Wahnschaffe U, Schulzke JD, Zeitz M, et al. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 844.
- Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366.
- Busch AJ, Schachter CL, Overend TJ, et al. Exercise for fibromyalgia: a systematic review. J Rheumatol 2008; 35: 1130.
- Villoria A, Serra J, Azpiroz F, et al. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol 2006; 101: 2552.
- Johannesson E, Simren M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106: 915.
- Ruepert L, Quartero AO, De Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011;(8):CD003460.
- Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313.
- Bijkerk CJ, De Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009; 339: b3154.
- The Cochrane Collaboration. Review manager (RevMan) [computer program]. Copenhagen: The Nordic Cochrane Centre; 2011.
- Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 87.
- Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 191.
- Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/peg 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1508.
- Bharucha AE, Pemberton JH, Locke GR 3rd. American gastroenterological association technical review on constipation. Gastroenterology 2013; 144: 218.
- Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655.
- Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877.
- Chey WD, Pare P, Viegas A, et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008; 103: 1217.
- Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344.
- Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329.
- US Food and Drug Administration. Detailed view: safety and labeling changes approved by FDA center for drug evaluation and research (CDER)—November 2012. Accessed March 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf.
- Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012; 35: 587.
- Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase c-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312.
- Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase c agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 86: 760.
- Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527.
- Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702.
- Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1084.
- Lembo A, Carson R, Shiff SJ, et al. Factors contributing to treatment satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) treated with linaclotide vs placebo. Gastroenterology 2012; 142: S822.
- Schoenfeld PS, Chang L, Carson R, et al. Do baseline factors contribute to treatment satisfaction in patients with chronic constipation treated with linaclotide vs placebo? Gastroenterology 2012; 142: S737.
- Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22.
- Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28.
- Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849.
- Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 775.
- Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012; 36: 437.
- Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115.
- Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662.
- Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733.
- Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035.
- Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195.
- Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006; 101: 1069.
- Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010; 105: 866.
- Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron post-marketing safety under the risk management program. Therap Adv Gastroenterol 2013; 6: 344.
- Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77: 225.
- Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011; 23: 1098.
- Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419.
- Shaheen NJ, Robertson DJ, Crosby MA, et al. Hyoscyamine as a pharmacological adjunct in colonoscopy: a randomized, double blinded, placebo-controlled trial. Am J Gastroenterol 1999; 94: 2905.
- Krueger D, Michel K, Allam S, et al. Effect of hyoscinebutylbromide (Buscopan) oncholinergic pathways in the human intestine. Neurogastroenterol Motil 2013; 25: e530.
- Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004; 10: 3561.
- Roman FJ, Lanet S, Hamon J, et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther 1999; 289: 1391.
- Abysique A, Lucchini S, Orsoni P, et al. Effects of alverine citrate on cat intestinal mechanoreceptor responses to chemical and mechanical stimuli. Aliment Pharmacol Ther 1999; 13: 561.
- Coelho AM, Jacob L, Fioramonti J, et al. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1a receptor subtype. J Pharm Pharmacol 2001; 53: 1419.
- Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome–a European perspective. Aliment Pharmacol Ther 2006; 24: 183.
- Wittmann T, Paradowski L, Ducrotte P, et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome–a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010; 31: 615.
- Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 432.
- Chang FY, Lu CL, Luo JC, et al. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 402.
- Guarner F, Requena T, Marcos A. Consensus statements from the workshop “probiotics and health: scientific evidence”. Nutr Hosp 2010; 25: 700.
- Kamiya T, Wang L, Forsythe P, et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55: 191.
- Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29: 104.
- Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination vsl# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687.
- Agostini S, Goubern M, Tondereau V, et al. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil 2012; 24: 376.
- Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48.
- Mccarthy J, O'mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975.
- Konieczna P, Groeger D, Ziegler M, et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012; 61: 354.
- Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581.
- Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387.
- Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis dn-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475.
- Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325.
- Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033.
- Mcfarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650.
- Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide. Aliment Pharmacol Ther 2013; 38: 864.
- Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159.
- Choung RS, Cremonini F, Thapa P, et al. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008; 20: 220.
- Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003; 1: 211.
- Morgan V, Pickens D, Gautam S, et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601.
- Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367.
- Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19.
- Camilleri M, Mayer EA. Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology 2009; 137: 766.
- Halpert A, Dalton CB, Diamant NE, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005; 100: 664.
- Thiwan S, Drossman DA, Morris CB, et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol 2009; 7: 446.
- Brennan BP, Fogarty KV, Roberts JL, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009; 24: 423.
- Van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6: 746.
- Hamner MB, Deitsch SE, Brodrick PS, et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003; 23: 15.
- Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2013; 11: 208.
- Craske MG, Wolitzky-Taylor KB, Labus J, et al. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther 2011; 49: 413.
- Kennedy T, Jones R, Darnley S, et al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ 2005; 331: 435.
- Ljotsson B, Hedman E, Andersson E, et al. Internet-delivered exposure-based treatment vs. Stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol 2011; 106: 1481.
- Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behav Res Ther 2009; 47: 797.
- Moss-Morris R, Mcalpine L, Didsbury LP, et al. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med 2010; 40: 85.
- Ljotsson B, Andersson G, Andersson E, et al. Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterol 2011; 11: 110.
- Vandulmen AM, Fennis JFM, Bleijenberg G. Cognitive-behavioral group therapy for irritable bowel syndrome: effects and long-term follow-up. Psychosom Med 1996; 58: 508.
- Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 1232.
- Lindfors P, Unge P, Arvidsson P, et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012; 107: 276.
- Forbes A, Macauley S, Chiotakakou-Faliakou E. Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome? Int J Colorectal Dis 2000; 15: 328.
- Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998; 23: 219.
- Palsson OS, Turner MJ, Johnson DA, et al. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002; 47: 2605.
- Roberts L, Wilson S, Singh S, et al. Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial. Br J Gen Pract 2006; 56: 115.
- Lindfors P, Unge P, Nyhlin H, et al. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scand J Gastroenterol 2012; 47: 414.
- Fernandez C, Perez M, Amigo I, et al. Stress and contingency management in the treatment of irritable bowel syndrome. Stress Health 1998; 14: 31.
- Van Der Veek PP, Van Rood YR, Masclee AA. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 943.
- Boyce PM, Talley NJ, Balaam B, et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 2209.
- Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011; 106: 1678.
- Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome. J Clin Gastroenterol 2011; 45: 593.
- Brown PM, Drossman DA, Wood AJ, et al. The tryptophan hydroxylase inhibitor lx1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507.
- Sohn W, Lee OY, Kwon JG, et al. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012; 24: 860.
- Drossman DA, Danilewitz M, Naesdal J, et al. Randomized, double-blind, placebo-controlled trial of the 5-HT1a receptor antagonist azd7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2562.
- Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549.
- Wong BS, Camilleri M, Mckinzie S, et al. Effects of a3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011; 106: 2154.
- Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011; 106: 1803.
- Simren M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation–a double-blind study. Aliment Pharmacol Ther 2011; 34: 41.
- Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245.
- Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77.
- Tack JF, Dochev YS, Bochenek A, et al. Efficacy of ibodutant, a selective antagonist of neurokinin 2 receptors, in irritable bowel syndrome with diarrhoea (IBS-D): the results of a double- blind, randomised, placebo-controlled, parallel-group phase II study (the IRIS-2). Gastroenterology 2013; 144: S92.
- Camilleri M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008; 20: 971.
- Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 239.
- Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 1268.
- Kelleher DL, Hicks KJ, Cox DS, et al. Randomized, double-blind, placebo-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron in patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20: 131.
- AltheRx Pharmaceuticals. Altherx Development Program, 2011. Accessed March 2013. Available at: http://www.altherx.com/development_program/default.asp.
- Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008; 78: 180.
- Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012;(5):CD005111.
- Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280: 1585.
- Bundy R, Walker AF, Middleton RW, et al. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complement Med 2004; 10: 667.
- Vejdani R, Shalmani HR, Mir-Fattahi M, et al. The efficacy of an herbal medicine, carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study. Dig Dis Sci 2006; 51: 1501.
- Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19: 271.
- Lu WZ, Gwee KA, Moochhalla S, et al. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927.
- Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402.
- Spence MJ, Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut 2007; 56: 1066.
- Nicholl BI, Halder SL, Macfarlane GJ, et al. Psychosocial risk markers for new onset irritable bowel syndrome – results of a large prospective population-based study. Pain 2008; 137: 147.
- Halder SL, Mcbeth J, Silman AJ, et al. Psychosocial risk factors for the onset of abdominal pain. Results from a large prospective population-based study. Int J Epidemiol 2002; 31: 1219.
- Lackner JM, Brasel AM, Quigley BM, et al. The ties that bind: perceived social support, stress, and IBS in severely affected patients. Neurogastroenterol Motil 2010; 22: 893.
- Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria – a 10-year follow-up study. Aliment Pharmacol Ther 2010; 32: 670.
- El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 861.
- Halder SLS, Locke GR, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799.
- Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605.
- Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831.
- Kennedy PJ, Clarke G, Quigley EM, et al. Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev 2012; 36: 310.
- Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil 2012; 24: 791.
-
Videlock EJ,
Chang L.
Irritable bowel syndrome. In:
N Talley (ed).
Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas.
Oxford, United Kingdom:
Wiley Blackwell;
2010.
10.1002/9781444328417.ch60 Google Scholar
